ArticleDiabetology & metabolic syndrome2025
Total bilirubin modifies the relationship between obesity and stroke.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTotal bilirubin (TBIL) is closely related to obesity, metabolic syndrome (MetS) and stroke. This study aimed to determine whether elevated TBIL could modify the association of obesity, MetS and stroke.
methodsWe included participants from the National Health and Nutrition Examination Survey from 2005 to 2018. TBIL was stratified according to the median (11.97µmol/L). Weighted logistic regression models were used to quantify the association between obesity, MetS, and stroke. Interactions were calculated with the use of likelihood ratio tests. Mediation analysis was used to determine whether elevated TBIL could inhibit the mediating factors between obesity and stroke.
resultsA total of 13,958 participants were included in the study. After adjusting for all confounding factors, obesity and MetS were independent risk factors for stroke (OR = 1.52, 95%CI 1.17–1.98; OR = 1.71, 95%CI 1.35–2.16). TBIL was associated with reduced risk of obesity and MetS (OR = 0.94, 95%CI 0.93–0.95; OR = 0.95, 95%CI 0.94–0.96) but not stroke. When TBIL < 11.97 µmol/L, obesity and MetS were associated with stroke (OR = 2.24, 95%CI 1.49–3.34; OR = 2.24, 95%CI 1.61–3.11), but when TBIL ≥ 11.97µmol/L, obesity and MetS were not associated with stroke (OR = 1.09, 95%CI 0.77–1.54; OR = 1.37, 95%CI 0.98–1.93). The interaction showed that elevated TBIL modified the association between obesity and stroke (P for interaction = 0.007), but not MetS (P for interaction = 0.089). Mediating effect analysis suggested that TBIL might change the relationship between obesity and stroke by inhibiting MetS.
conclusionElevated TBIL may change the relationship between obesity and stroke by inhibiting the mediating effect of MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.